Truqap is actually a kinase inhibitor that works by blocking pathways that support the cancer cells survive and improve, so minimizes cancer growth. Truqap is from a category of medicines called an AKT inhibitor. Truqap obtained FDA approval on November seventeen, 2023, following optimistic results in the CAPItello-291 Phase III https://6-hydroxypaclitaxel57801.targetblogs.com/35248582/considerations-to-know-about-capivasertib